Studies by Kaikkonen et al., in 2018 revealed that mutations in the Anoctamin 7 (ANO7) gene could serve as an effective biomarker for early detection of advanced prostate cancer [20]. This evidence concerns the gene ANO7 and Familial prostate cancer.